ArticleClinical medicine & research2024
Reversible Cerebral Vasoconstriction Syndrome Secondary to Escitalopram.
Article in Clinical medicine & research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reversible Cerebral Vasoconstriction Syndrome Associated With Vortioxetine: A Case Report.Cureus · 2026Article
- The onset of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with the use of decongestant agents: a European pharmacovigilance analysis.Pharmacological reports : PR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversible cerebral vasoconstriction syndrome (RCVS) is a relatively rare and underdiagnosed neurological condition that has similar clinical presentation to other neurological emergencies. Antidepressants such as selective serotonin reuptake inhibitors can be a secondary cause of RCVS. We present the case of a healthy young woman, with long term escitalopram use, who presented with bilateral neurological deficits and was found to have RCVS, whose symptoms improved remarkably after intra-arterial calcium channel blocker treatment. We discuss risk factors, theorized mechanisms, presentation, diagnostic tools, and management of RCVS. Our case should serve as a corollary for physicians to consider RCVS as a differential diagnosis for thunderclap headache, especially in patients with selective serotonin reuptake inhibitor use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.